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Abstract
Background Infection with high-risk subtypes of human
papillomavirus (HPV) is a central factor in the development
of cervical neoplasia. Cell-mediated immunity against
HPV16 plays an important role in the resolution of HPV
infection and in controlling cervical disease progression.
Research suggests that stress is associated with cervical
disease progression, but few studies have examined the
biological mechanisms that may be driving this association.
Purpose This study examines whether stress is associated
with immune response to HPV16 among women with
cervical dysplasia.
Methods Seventy-four women presenting for colposcopy
completed measures of health behaviors, stressful life events
and perceived stress. A blood sample was obtained to
evaluate proliferative T-cell response to HPV16, and a
cervical sample was obtained during gynecologic exam for
HPV-typing.
Results More than 55% tested positive for one or more
HPV subtypes. Women who did not show proliferative
responses to HPV (i.e. non-responders) were more likely to
be HPV+ compared to women who had a response (i.e.
responders). Consistent with study hypotheses, logistic
regression revealed that higher levels of perceived stress were
associated with a non-response to HPV16, controlling for
relevant covariates. Stressful life events were not associated
with T-cell response to HPV.
Conclusions Higher levels of perceived stress are associ-
ated with impaired HPV-specific immune response in
women with cervical dysplasia, suggesting a potential
mechanism by which stress may influence cervical disease
progression.
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Introduction
Infection with specific subtypes of human papillomavirus
(HPV) has been shown to contribute to the development of
cervical neoplasia [1–4]. Of the more than 70 HPV
subtypes found to infect the anogenital tract, 15 have been
identified as high-risk subtypes because they are associated
with an increased risk of cervical cancer. Among high-risk
(HR) HPV subtypes (e.g., HPV types 16, 18, 31, 45, and 56),
HPV16 is the most common subtype that is associated with
cervical neoplasia and carcinoma of the cervix [5]. However,
HPV infection alone is not sufficient to cause cervical
cancer [4, 6]. Indeed, the cumulative lifetime probability of
acquiring a cervical infection with at least one type of HPV
is extremely high for sexually active women [7]. Yet, most
HPV infections in healthy, immunocompetent women will
resolve spontaneously over time, and only a small percent-
age progress to precancerous cervical lesions [8–10]. The
finding that HPV infection is far more common than
cervical neoplasia suggests that there are cofactors for the
progression of HPV infection to cervical cancer.
One potential cofactor that has been extensively studied
is the role of cell-mediated immunity in resolving HPV
infection. Correlative studies have demonstrated that
increasing level of immunosuppression is associated with
increased risk of cervical intraepithelial neoplasia (CIN)
and cervical cancer. For example, women with symptomatic
human immunodeficiency virus (HIV) infection (and
therefore, greater immunosuppression) were more likely to
be HPV+ and at greater risk for CIN compared to their
asymptomatic and relatively immunocompetent HIV+ and
HIV- counterparts [11, 12]. Increased risk of developing
high-grade cervical lesions among HIV+ women appeared
to be due to increased HPV persistence that resulted from
immunosuppression related to HIV infection [13].
Over the past decade, researchers have identified specific
HPV16 peptides to which cell-mediated immune responses
correlated significantly with the absence of HPV infection
(and the presumed resolution of infection) and with
regression of CIN at subsequent clinic visits. Using synthetic
peptides derived from HPV16 as sources of antigens in cell-
mediated immune assays, these studies found that women
who displayed positive T-cell proliferative responses to
HPV16 peptides in vitro were significantly more likely to
be HPV negative than were nonresponders, suggesting that
cell-mediated immune responses were associated with the
resolution of HPV infection [14]. Moreover, in a longitudi-
nal study of women with CIN I and CIN II, lymphoproli-
ferative responses to HPV16 peptides significantly
predicted resolution of viral infection and regression of
cervical disease at subsequent clinic visits [15]. Absent
responses (i.e., nonresponse) correlated with persistent
genital HPV infection as well as with persistent disease
[15]. Although these findings are supportive of the immune
surveillance theory, they do not provide direct evidence of a
cause-and-effect relationship between immune dysregula-
tion and development of HPV-related cervical disease.
As such, more recent studies have attempted to elicit
HPV-specific immune responses to demonstrate that cell-
mediated immunity to HPV is associated with the regres-
sion or prevention of cervical neoplasia or cancer [6].
Indeed, this hypothesis serves as the rationale for the
development of prophylactic HPV vaccines. Prophylactic
vaccines against HPV use virus-like particles (VLPs) based
on proteins derived from HPV to stimulate an immune
response. Data from several randomized clinical trials
indicate that HPV VLP vaccines are effective in generating
HPV-specific cell-mediated immunity and in preventing
persistent HPV infection and cervical dysplasia [16–18].
Although the development of the HPV vaccine represents a
very promising step toward eradicating cervical cancer, it will
be decades before the projected benefits of lower incidences of
cervical preinvasive and invasive disease are actually observed,
due to the long latency from HPV infection to the development
of precancerous lesions and cancer [19]. In addition, because
the vaccines provide immunity against only selected HPV
types, vaccinated women are advised to continue getting Pap
smears to detect precancerous lesions caused by other high-
risk HPV subtypes [20]. At present, it is recommended that
the vaccine be administered to young women and girls who
are not yet sexually active and have not been exposed to HPV
[20, 21], thereby leaving a substantial proportion of women
who are not candidates to receive the vaccine. As a result,
there will still continue to be large numbers of women who
are diagnosed with HPV infection and CIN, until future
generations when the majority of women and girls have had
the opportunity to receive the vaccine. Thus, cervical disease
will still remain a relevant health concern for the population
of women who are currently sexually active.
Given the likely role of immune factors in HPV-related
conditions, cervical dysplasia presents a unique disease model
with which to examine proposed biobehavioral pathways
between stress and health outcomes. Indeed, previous studies
have reported that higher levels of stress are associated with
cervical disease progression [22, 23]. Among a sample of 32
HIV-infected women, higher life stress was associated with
greater risk for persistent or progressive cervical lesions [23].
Similarly, a separate study revealed that stressful life events
were associated with cervical disease progression [22]. Few
studies, however, have examined the biological mechanisms
by which stress may contribute to increased risk for cervical
disease progression.
Thus, the purpose of the present study was to examine
whether psychosocial stress is associated with immune
response to specific HPV16 proteins. To do so, we first set
out to confirm that patients with cervical dysplasia have a
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deficient T-cell proliferative response to HPV16 in com-
parison to healthy controls. We then examined potential
associations between psychosocial stress and T-cell re-
sponse to HPV in our patient sample, given the important
role that cell-mediated immunity may play in controlling
HPV infection and cervical disease progression. Based on
previous studies that demonstrated that psychological stress
is associated with immune alterations in healthy individuals
[24–26] as well as cancer patient populations [27], we
hypothesized that greater levels of stress would be
associated with impaired (absent) T-cell proliferative
response to HPV16 among women with cervical dysplasia.
Methods
Participants
One hundred and thirty-two women presenting for colpo-
scopy at a cancer center or a university medical center
following an abnormal Pap smear test result indicative of
low-grade squamous intraepithelial lesions (LGSIL) were
contacted before their exams. Exclusion criteria included
presence of a co-morbid condition with effects on the
immune system (e.g., autoimmune disorder, HIV-positive
status), history of previous cervical cancer or a current
cancer diagnosis, currently pregnant, or use of systemic
steroid medication within the previous 3 months. There
were 7 women determined to be ineligible due to exclusion
criteria, 35 women declined to participate, and 12 partic-
ipants were excluded from analysis because their subse-
quent biopsy results indicated normal or benign cellular
changes and no evidence of cervical dysplasia, resulting in
a sample of 78 patients with biopsy-confirmed CIN I-II.
Three participants had insufficient blood samples for the
proliferative assays. A laboratory error occurred in process-
ing one sample, leaving a total of 74 patients with viable
samples. In addition, 68 healthy women were contacted to
serve as controls. Women in the control group were
presenting for routine annual gynecologic exam and had
no prior history of cervical disease. Similar exclusion
criteria applied to control group participants. There were 4
women determined to be ineligible and 36 women declined
to participate, resulting in a sample of 28 healthy controls.
Procedure
Potential participants were identified by collaborating physi-
cians and were referred to a study research assistant. The
research assistant met with each participant in the clinic to
describe the study protocol and to obtain written informed
consent. The patients completed measures of demographic
characteristics, health behaviors, and psychosocial stress.
Healthy controls completed an abbreviated questionnaire
containing a subset of demographic items and health
behaviors. Following the completion of the questionnaire, a
blood sample (20 ml) was drawn from each participant by
a trained phlebotomist. Each participant then underwent a
gynecologic exam, during which a small cervical brush was
used to obtain cells from the cervix for HPV-typing.
Measures
Demographic Variables and Health Behaviors
Age, marital status, and education level were assessed. The
participants also completed items measuring relevant health
behaviors, including current smoking status and sexual and
reproductive history variables, which are associated with
increased cervical cancer risk (e.g., age at first intercourse,
number of sexual partners).
Stressful Life Events and Perceived Stress
Because research has demonstrated that both major life
events and minor daily hassles contribute to stress [28], we
opted to utilize two measures of stress: an objective, life
events measure and a subjective measure of perceived
stress. Stressful life events were assessed using a shortened
and modified version of the Holmes-Rahe Social Readjust-
ment Rating Scale [29]. The modified checklist contained
12 events that were selected for their relevance to this
population and included items such as death of a close
family member, marital separation, personal injury or
illness, incarceration, serious illness in a family member,
financial difficulties, change in living conditions, loss of
income (i.e., being fired from work), relationship problems,
physical and sexual violence against self, problems caused
by substance use, and change in children’s residence (i.e.
residing elsewhere). The participants were asked to indicate
whether each event had occurred in the past 6 months. The
occurrence of each event was marked as a ‘1’ and all events
were summed to create a total score. Possible scores ranged
from 0–12.
Perceived stress was assessed using the Perceived Stress
Scale (PSS [30]). This 14-item scale is designed to measure
the degree of perceived stress in one’s life over the past
month. The PSS has demonstrated strong internal reliability
and has been found to be associated with physical
symptomatology and illness [30–35]. Cronbach’s α in the
present sample was 0.86.
HPV DNA Testing
Viral typing was conducted using the Hybrid Capture II
HPV typing methodology from Digene Corporation (Gai-
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thersburg, MD). Cervical swab specimens were obtained
from all patients during gynecological examination. Swabs
were placed in a transport solution and the exfoliated cells
were digested by proteolytic enzymes. DNA was denatured
and hybridized with an RNA probe cocktail. Two probe
cocktails (one each for high- and low-risk subtypes) were
hybridized to the specimen. The DNA/RNA hybrids were
captured on a solid phase and reacted with fluorescently
tagged antibodies, resulting in signal amplification. The
level of fluorescence was measured by luminometer in a
microplate format. HPV types targeted in the high risk
probe cocktail included HPV 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 68. HPV types targeted in the low risk probe
cocktail included HPV 6, 11, 42, 43, 44. Among cases that
were positive for high-risk subtypes, we tested for the
presence of HPV16 with an HPV16-specific probe using
the same methodology.
Immune Measures
To assess functional T-cell response to HPV, we utilized
synthetic peptides derived from HPV16 E6, E7, and L1 open
reading frames, which were selected based upon prior
studies of T-cell response to HPV16 [36, 37]. The specific
peptide sequences used in the present study were (1)
TELQTTIHDILECVYCKQQLL, corresponding to HPV16
E6 amino acids 24–45, (2) QAEPDRAHYNIVTF,
corresponding to E7 amino acids 44–57, and (3)
LNTNFKEYLRHGEEY, corresponding to L1 amino acids
382–396. All peptides were commercially prepared by
Invitrogen Corporation (Carlsbad, CA, USA) using standard
Fmoc chemistry. The purity of the peptides was greater than
95% in all preparations. In this procedure, PBMCs were plated
in triplicate at 105 cells/well in 96-well round-bottom micro-
titer plates with each of the synthetic peptide antigens in a
total volume of 200 μl of RPMI 1640 with 20% pooled
human serum, 1,000 U of penicillin G per milliliter, and
1,000 mg of streptomycin per milliliter. The microtiter plates
were incubated at 37°C in a CO2 incubator for 6 days. Cell
proliferation was measured by pulse labeling cells for DNA
synthesis for 6 h with tridiated thymidine 1 μCi/well.
Cellular DNA were collected onto glass microfiber filters
using a multiple automated sample harvester, counted in a
liquid scintillation counter and counts per minute determined
[38–40]. Data were expressed as mean counts per minute and
stimulation indices compared to negative control wells. For
each subject, the median count per minute was used to
calculate the stimulation index (SI) in the following formula:
SI=(median count per minute of antigen-stimulated well)/
(median count per minute of negative control [antigen-free]
well). It is standard practice to use a SI value of ≥3.0 as a
cutoff value to indicate positive responses in tridiated-
thymidine incorporation assays measuring proliferative re-
sponse. Similar studies assessing T-cell proliferative response
to HPV have used this cutoff value as well [37, 41].
Therefore, for comparisons of proliferative response,
the subjects were classified as responders if their SI was
≥3.0. Proliferative responses to tetanus toxoid (recall
antigen) and pokeweed mitogen were also assessed for each
subject.
To evaluate whether potential differences in functional
T-cell response to HPV16 could be due to variations in the
number of circulating T cells, we also obtained a quantita-
tive assessment of select lymphocyte subsets. Enumeration
of cell phenotypes was determined using three-color flow
cytometry. Cell subsets assessed were helper T-cells (CD4+/
CD3+), cytotoxic/suppressor T-cells (CD8+/CD3+), and
natural killer (NK) cells (CD3-/CD56+). Samples were
prepared by direct immunofluorescent staining of erythro-
cyte-lysed whole blood and analyzed on a Becton
Dickinson FACScan flow cytometer. Specific procedures
have been previously reported [42]. The data presented
are expressed as the absolute number of cells per unit
volume bearing the marker, which were calculated using
data derived from the complete blood count (CBC)
and differential obtained on each sample at the time of
analysis.
Data Analysis
Data were analyzed using SPSS Version 14.0. Descriptive
statistics were used to characterize the sample with respect to
demographic characteristics, behavioral risk factors, and
immune status. To address the first study objective (i.e., do
patients and healthy controls differ in T-cell response to
HPV16?), we examined group differences between patients
and controls in the presence of HPV DNA and T-cell
proliferative response to HPV using Pearson χ2 tests for
categorical variables (e.g., HPV-positivity, proliferative re-
sponse). Based on previous studies, it was hypothesized that
patients would be less likely to show T-cell responses to
HPV16 compared to controls. To address the second study
objective (i.e., is psychosocial stress associated with T-cell
response to HPV16?), we first identified potential covariates
using simple logistic regression analyses with overall T-cell
proliferative response to HPV16 as the dichotomous
outcome variable. Demographic and behavioral factors were
entered as independent variables in separate models. Factors
found to be associated with the outcome variable were
entered as covariates in the multivariate logistic regression
analysis to examine the hypothesis that psychosocial stress is
associated with a proliferative T-cell non-response to HPV16.
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Results
Characteristics of the Study Sample
Seventy-four women with abnormal cervical cytology (i.e.,
patients) and twenty-eight healthy women without cervical
disease (i.e., controls) were studied (Table 1). No differ-
ences in mean age or educational level were observed.
Although it appears that a greater proportion of patients
were married or living with a partner (43.5%) compared to
controls (25.0%), this difference did not reach statistical
significance, χ2(1)=2.88, p=0.09.
With respect to HPV status, 50% (37/74) of patients tested
positive for high-risk HPV subtypes (HPV-16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 68), and 38% of those women (14/
37) tested positive specifically for HPV16. Twenty-one
percent (16/74) tested positive for low-risk HPV subtypes
(HPV-6, 11, 42, 43, 44). Overall, 55.4% (41/74) tested
positive for one or more HPV subtypes. Among healthy
controls, 17.9% (5/28) tested positive for high-risk HPV
subtypes and 60% of those women (3/5) were positive for
HPV16. No controls tested positive for low-risk HPV
subtypes. Overall, 5 of 28 controls (17.9%) were HPV-
positive. As expected, patients were significantly more likely
to be HPV-positive (55.4%) compared to controls (17.9%),
χ2(1)=11.57, p<0.001.
With respect to reproductive and sexual history, patients
and controls did not differ on mean age at first intercourse.
However, the median number of recent sexual partners was
higher among patients than controls (Mann–Whitney U=
717.00, Z=−2.31, p=0.02). Patients were less likely to be
nulliparous (39.3%) compared to controls (75.0%), χ2(1)=
9.76, p<0.01. With respect to health behaviors, no differ-
ences in oral contraceptive use or smoking status were
observed. Numbers of circulating T and NK cells were also
examined by group. No differences in T cell subsets (either
helper T or cytotoxic/suppressor T cells) were observed
between patients and controls. However, patients had higher
numbers of NK cells (M=357.20, SD=240.21) compared to
controls (M=228.67, SD=144.37), F(1,101)=5.85, p<0.02.
T-cell Response to HPV-16 Peptides in Relation
to Participant Group and HPV Status
Short-term proliferation assays were performed with peptides
derived from the HPV16 proteins E6, E7, and L1. The range
of SIs spanned from 0.0 to 337.60, although the median SI
ranged between 1.90–2.45 for each of the three peptide
sequences tested. The percentage of subjects displaying
positive T-cell proliferative responses is depicted in Table 2.
Responses to each of the three peptides were detected in
some subjects. Across the entire sample, 48% (49/102)
displayed no proliferative response to any of the peptides,
whereas 36% (37/102) responded to all three peptides.
Among patients, the percentage who displayed a positive
proliferative response ranged from 37 to 42%, depending
upon the peptide sequence. Although 51% (38/74) of patients
did not show a proliferative response to any of the antigens, all
patients displayed responses to the recall antigen (tetanus) and
pokeweed mitogen. Responses to tetanus and pokeweed
mitogen did not differ between patients and controls (χ2
values for both the recall antigen and pokeweed <1.0, n.s.).
Among healthy controls, proliferative response ranged from
46 to 61%. Rates of reactivity were significantly higher in
response to the L1382–396 peptide in controls (61%)
compared to patients (37%), χ2(1)=4.86, p<0.03.
Proliferative response was also associated with HPV-status
in the patient group. A significantly greater proportion of
HPV16-negative patients displayed proliferative responses to






Mean age (SD) 32.76 (11.48) 35.52 (10.25)
Range 19–64 18–54
Education
Grade school 21.6% 25.0%









Mean age at first
intercourse
16.48 (2.34) 16.52 (1.85)
Range 9–22 14–21







Use oral contraceptives 32.8% 14.3%
Current smoker 34.3% 42.9%
Immune cell subsets






742.04 (422.31) 840.48 (352.60)
NK cells (cells/mm3)* 357.20 (240.21) 228.67 (144.37)
*Significant difference between patients and controls, p<0.05.
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each peptide compared to their HPV16-positive counterparts.
As illustrated in Table 2, 47% (28/60) of HPV16-negative
patients were positive “responders” to E624–45 compared to
only 14% (2/14) of HPV16-positive patients, χ2(1)=4.94,
p<0.03. This association was also observed for E744–57 and
L1382–396 peptides, both χ
2(1)s>5.40, ps<0.03.
To assess whether differences in functional T-cell
response to HPV16 may be due, in part, to variations in
the number of circulating T cells, we conducted a one-way
ANOVA by proliferative response status (i.e., responders vs
nonresponders). No differences in helper T cells, cytotoxic/
suppressor T cells, or NK cells were found between
responders and nonresponders, thereby suggesting that the
observed differences in functional response were not due to
discrepancies in the absolute number of T cells. Moreover,
as mentioned above, all participants displayed proliferative
responses to pokeweed, and therefore, the observed
nonresponse appears to be HPV-specific and not indicative
of general immune dysfunction.
In sum, the findings from our first set of analyses
demonstrate that T-cell proliferative responses to HPV16 are
less likely to be observed in cervical dysplasia patients
compared to healthy controls. Furthermore, proliferative
responses were also less likely to be displayed among
HPV16-positive patients compared to HPV16-negative
patients. In the patient sample, over 51% (38/74) did not
display a response to any of the peptides, and 32.4% (24/74)
displayed a response to all of the peptides. Thus, for
subsequent analyses, T-cell proliferative response was dichot-
omized as positive or negative for cell-mediated immunity to
HPV16, similar to previous studies [14], in the following
manner: patients who did not display any proliferative
responses were categorized as complete nonresponders (N=
38); participants who displayed a positive response to at least
one peptide were categorized as responders (n=36).
Evaluating the Association Between Stress and Functional
Immune Response to HPV16
Given that impaired T-cell responses to HPV16 have been
associated with persistent HPV infection and disease progres-
sion in patients with cervical dysplasia [14, 15, 36, 37], we
examined the hypothesis that psychosocial stress would be
associated with immune response to HPV16 in the patient
subgroup. Among patients, the mean level of perceived stress
was 26.56 (SD=8.76). The median number of life events
reported during the past 6 months was 1 (mean=1.91, SD=
1.69, range=0–6), with 22% reporting no life events, 28%
reporting 1 event, 22% reporting 2 events, 14% reporting 3
events, and 15% reporting 4 or more stressful events.
To identify potential covariates for inclusion in the
multivariate model, we conducted simple logistic regression
analyses using demographic variables and behavioral risk
factors as independent predictors of the outcome variable.
As described earlier, current HPV16 infection was associ-
ated with T-cell proliferative responses. In addition, marital
status (i.e., married or living with a partner vs single/
divorced/widowed) and current smoking status were asso-
ciated with T-cell proliferative response to HPV. Specifi-
cally, current smokers were less likely to have a T-cell
proliferative response to HPV16 compared to nonsmokers,
OR=0.32, 95% CI=0.11–0.97, p<0.05. In addition, women
who were married or living with a partner were more likely
to be “responders” compared to women who were single or
divorced, OR=2.91, 95% CI=1.07–7.91, p<0.05. In light
of this association between marital status and proliferative
response, we examined whether marital status was a
“proxy” for HPV16-positivity (i.e., women with a partner/
spouse may be less likely to be exposed to HPV16 than
women who are currently single or divorced). In chi-square
analysis, no significant association was observed between
marital status and HPV16-positivity, χ2(1)=1.40, p<0.20.
Thus, based on the findings that T-cell proliferative
response to HPV16 was associated with current HPV16
infection, marital status and smoking status, these variables
were included as covariates in the subsequent analysis.
A logistic regression analysis was performed to evaluate
the association between perceived stress and life events with
immune response to HPV. Variables in the model were entered
in three steps (see Table 3). The first step contained
demographic covariates (i.e., marital status). Relevant risk
factors, including current infection with HPV16 and smoking
Table 2 Proliferative T-cell responses to HPV-16 synthetic peptides by group and HPV-status
Peptide Patients (N=74) Healthy controls (N=28)
All HPV16+ HPV16- All HPV16+ HPV16-
E624–45 41% (30/74) 14% (2/14)* 47% (28/60)* 46% (13/28) 67% (2/3) 44% (11/25)
E744–57 42% (31/74) 14% (2/14)* 48% (29/60)* 46% (13/28) 67% (2/3) 44% (11/25)
L1382–396 37% (27/74)** 7% (1/14)* 43% (26/60)* 61% (17/28)** 67% (2/3) 60% (15/25)
The percentages reflect the number of subjects with SI≥3.0 (i.e., responders)/number of subjects tested
*Significant difference between HPV16+ and HPV16- patients in proliferative response, p<0.05; **Significant difference between patients and
control in proliferative response, p<0.05
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status, were entered on the second step. Psychosocial
variables (i.e., perceived stress and number of stressful life
events) were entered simultaneously on the third step. After
controlling for demographic and behavioral covariates, the
model revealed that higher levels of perceived stress were
associated with nonresponse to HPV16, OR=0.91, 95% CI=
0.85–0.98, p<0.05. Number of life events was not signifi-
cantly associated with proliferative response to HPV. The
goodness-of-fit for the logistic regression model was
evaluated using the Hosmer-Lemeshow statistic. The final
model demonstrated good fit, χ2(7)=8.78, p=0.27.
Discussion
In our analysis of healthy women and women with CIN, the
absence of T-cell proliferative response to HPV16 synthetic
peptides was observed to be associated with the presence of
clinical disease and current HPV infection. These findings
are similar to data reported in previous studies [36, 37, 43,
44] in which healthy women were more likely to show
positive T-cell proliferative responses to HPV16 compared
to women with abnormal cervical cytology. In addition, our
findings are also consistent with prior studies that have
reported lymphoproliferative responses to HPV16 peptides
to be correlated with current status of HPV infection [14].
However, the cross-sectional design of the current study
makes the interpretation of the positive proliferative
response to HPV16 peptides among women who are
HPV-negative somewhat ambiguous. One potential expla-
nation for this finding is that patients with CIN who are
HPV16-negative previously had a cervical HPV infection,
which has been cleared. The resolution of HPV infection is
likely to precede the spontaneous regression of HPV-related
lesions over time [45]. In contrast, persistent HR-HPV
infection is associated with progression to CIN III or cancer.
Data from longitudinal studies also support this explanation,
as lymphoproliferative responses to HPV16 in vitro have
been found to be predictive of resolution of HPV infection in
vivo and regression of HPV-related cervical disease at
follow-up time points [15]. Although this scenarios is
plausible, the cross-sectional design of the present study
makes it impossible to definitively determine the basis for
this association because data on whether these women were
HPV16 positive at some previous time point are lacking.
Data from the present study also indicated that perceived
stress is associated with impaired functional T-cell response
to HPV16 in vitro, a measure that has been shown to be
predictive of viral persistence and subsequent clinical
disease progression in vivo [15]. In light of previous
studies that have reported psychological stress to be
associated with increased risk for the development and
progression of CIN [22, 23, 46], our findings underscore
one biological pathway by which stress may lead to greater
susceptibility to cervical neoplasia and cancer.
These data are consistent with previous studies that have
reported psychological stress to be associated with lower
functional indices of immunity (e.g., lymphocyte proliferative
response to mitogens and natural killer cell activity) across a
variety of populations, including healthy adults, bereaved
individuals, and HIV+ gay men [47]. But this study is the
first to demonstrate such a relationship between stress and
HPV-specific immune response among women at risk for
cervical cancer. Given that impaired T-cell response to HPV is
predictive of cervical disease progression, the association
between perceived stress and cell-mediated immune response
to HPV offers support for a biobehavioral model of cervical
cancer risk [46], especially among immunocompetent women.
We observed that functional T cell response to HPV was
not contingent upon the absolute number of circulating Tcells,
as responders and nonresponders did not differ on enumera-
tive measures of T-cell subsets. It is more likely that stress
effects on T-cell response to HPV are mediated by stress-
induced changes in Th1 and Th2 cytokine production. Prior
studies have shown that stress is generally associated with
decreased production of Th1 cytokines (which are essential to
mounting a protective response against infectious agents), but
increased production of Th2 cytokines (which are involved in
humoral immunity [48]). This shift from a Th1 to Th2
cytokine profile has also been reported to be associated with
more extensive HPV infection and disease [49].
Although perceived stress was associated with T-cell
response to HPV, life events were not. This was somewhat
unexpected as Coker and colleagues found that a greater
number of stressful life events was associated with
increased risk of SIL among white women [22]. In that
Table 3 Factors associated with overall T-cell response to HPV16 in
women with cervical dysplasia (N=74)




Married/living with partner 1.88 (0.58, 6.07)
(2) Cervical cancer risk factors
Presence of HPV16 DNA
No 1.00a
Yes 0.12 (0.02, 0.72)**
Current smoking status
Non-smoker 1.00a
Smoker 0.76 (0.23, 2.52)
(3) Psychosocial variables
Perceived stress 0.91 (0.85, 0.98)*
Life events 1.37 (0.93, 2.02)
*p<0.05. **p<0.01
a Reference group
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prior study, both the number of stressful life events as well
as the perceived impact of those events was associated with
disease risk. However, the authors noted that the measure of
high-impact life events was superior to the pure number of
events experienced, which is consistent with our findings from
the present study and from a broader review of the literature.
For example, among patients with lupus (an autoimmune
disorder), daily stress, but not stressful life events, was related
to clinical symptomatology [50]. In the context of upper
respiratory infections, it has often been the case that stressful
life events, by themselves, have not directly predicted illness
[51]. Rather, the association between life events and health
outcomes may be more likely to be observed under certain
conditions or in a particular subgroup of individuals (e.g.,
individuals with low social support).
In the present study, the assessment of life events
encompassed events that occurred over the previous
6 months, whereas women’s ratings of perceived stress were
more proximal (i.e., during the past month). Thus, the specific
nature of the relationship between immune outcomes and
particular stress measures may be due to a “time” factor. A
longer interval between the experience of life events and the
assessment of immune function is likely to contribute to
disparate findings, as exposure to events that occurred several
months or years in the past may not have the same impact on
current cell-mediated immunity as the effect of one’s perceived
stress levels over the past week or month. Finally, it has been
argued that the assessment of life events is often not as strongly
related to health outcomes as one would expect because how
an individual appraises and copes with each event is likely to
lead to varying outcomes [52, 53]. Studies have demonstrated
that the cognitive appraisal of a stressor affects the subsequent
physiological responses to that stressor [54], suggesting the
relative importance of one’s appraisal of a stressful event over
the objective occurrence of that event in determining health
outcomes. For example, high levels of stressful life events
predicted respiratory illness, but only among those individu-
als who exhibited high physiological reactivity to a laboratory
stressor (i.e., high reactors) [32]. Life events did not predict
illness among low reactors.
We acknowledge several potential limitations of this
study. One limitation is that local immune factors (i.e., from
the genital tract mucosa) were not assessed. However, given
that previous studies have shown that a systemic immune
response to HPV is predictive of viral clearance and disease
course [55], we chose to focus our assessments on those
that have been demonstrated to be associated with clinical
outcomes. Second, within the cross-sectional design of the
present study, causal inferences regarding the effects of stress
on immune response to HPV cannot be established.
Randomized trials to evaluate whether changes in psycho-
logical stress lead to subsequent changes in functional
immune response to HPV will be necessary to ascertain the
causal nature of this association. Finally, because the healthy
control participants did not complete the psychosocial
questionnaires, we were not able to evaluate the association
between stress and proliferative response among healthy
women. Therefore, the generalizability of the present
findings to the larger population of sexually active women
is undetermined. Additional studies with larger samples of
healthy women will be needed to address this question.
In summary, there has been considerable interest in
understanding whether and how psychosocial stress may
influence health via alterations in biological functioning.
Although a number of studies have been conducted to
address this question, many studies have tended to utilize
biological assessments for which the clinical relevance and
disease-specific implications are not well-defined. In
addition, few studies have examined the mechanisms
underlying the proposed stress-health association in pop-
ulations at increased risk for cancer; yet, these mechanisms
are particularly relevant in the context of cervical cancer, a
virally induced cancer. The present study offers a greater
understanding of the processes underlying the association
between psychological stress and cervical cancer risk.
Additional studies are now warranted to investigate the
extent to which changes in psychosocial factors result may
lead to alterations in biobehavioral pathways that contribute
to greater susceptibility to cervical cancer.
Acknowledgement This research was supported by National Institutes
of Health grants K22CA107115, R01CA125069, CA006927,
P30AI45008–07, and M01RR00240–34. We thank Louella Pritchette,
AmyDevlin, Tana Connolly, Nancy Tustin, Nancy Raftery, and Eric Reidel
for their assistance on this project. We acknowledge the FCCC Biosample
Repository and the Stokes Flow Cytometry Core for their services.
References
1. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of
the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation
to papillomavirus infection. N Engl J Med. 1992; 327: 1272–1278.
2. Stoler MH. A brief synopsis of the role of human papillomaviruses in
cervical carcinogenesis.Am J Obstet Gynecol. 1996; 175: 1091–1098.
3. Wolf JK, Franco EL, Arbeit JM, et al. Innovations in understand-
ing the biology of cervical cancer. Cancer. 2003; 98: 2064–2069.
4. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical
cancer. Cancer J. 2003; 9: 348–359.
5. Mitchell MF, Tortolero-Luna G, Wright T, et al. Cervical human
papillomavirus infection and intraepithelial neoplasia: a review. J
Natl Cancer Inst Monographs. 1996; 21: 17–25.
6. Schoell WMJ, Janicek MF, Mirhashemi R. Epidemiology and
biology of cervical cancer. Sem Surg Oncol. 1999; 16: 203–211.
7. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV
infection among females in the United States. J Am Med Assoc.
2007; 297: 813–819.
8. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of
high-grade cervical neoplasia risk among human papillomavirus-
infected women. J Natl Cancer Inst. 2002; 94: 1406–1414.
94 ann. behav. med. (2008) 35:87–96
9. Schiffman MH, Castle P. Epidemiologic studies of a necessary
causal risk factor: Human papillomavirus infection and cervical
neoplasia. J Natl Cancer Inst. 2003; 95: E2.
10. Castle PE, Solomon D, Schiffman M, Wheeler CM. Human
papillomavirus type 16 infections and 2-year absolute risk
of cervical precancer in women with equivocal or mild
cytologic abnormalities. J Natl Cancer Inst. 2005; 97: 1066–
1071.
11. Vermund SH, Kelley KF, Klein RS, et al. High risk of human
papillomavirus infection and cervical squamous intraepi-
thelial lesions among women with symptomatic human immuno-
deficiency virus infection. Am J Obstet Gynecol. 1991; 165:
392–400.
12. Maiman M. Management of cervical neoplasia in human
immunodeficiency virus-infected women. J Natl Cancer Inst
Monographs. 1998; 1998: 43–49.
13. Hawes SE, Critchlow CW, Sow PS, et al. Incident high-grade
squamous intraepithelial lesions in Senegalese women with and
without human immunodeficiency virus type 1 (HIV-1) and HIV-
2. J Natl Cancer Inst. 2006; 98: 100–109.
14. Kadish AS, Ho GYF, Burk RD, et al. Lymphoproliferative
responses to human papillomavirus (HPV) type 16 proteins E6
and E7: Outcome of HPV infection and associated neoplasia. J
Natl Cancer Inst. 1997; 89: 1285–1293.
15. Kadish AS, Timmins P, Wang Y, et al. Regression of cervical
intraepithelial neoplasia and loss of human papillomavirus (HPV)
infection is associated with cell-mediated immune responses to an
HPV type 16 E7 peptide. Cancer Epidemiol Biomark Prev. 2002;
11: 483–488.
16. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a
human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347:
1645–1651.
17. Washam C. Two HPV vaccines yielding similar success. J Natl
Cancer Inst. 2005; 97: 1030.
18. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent
human papillomavirus (types 6, 11, 16, and 18) L1 virus-like
particle vaccine in young women: a randomised double-blind
placebo-controlled multicentre phase II efficacy trial. Lancet
Oncol. 2005; 6: 271–278.
19. Mahdavi A, Monk BJ. Vaccines against human papillomavirus
and cervical cancer: promises and challenges. Oncologist. 2005;
10: 528–538.
20. Shaw AR. Human papillomavirus vaccines in development: if
they’re successful in clinical trials, how will they be imple-
mented? Gynecol Oncol. 2005; 99: S246–S248.
21. Washam C. Targeting teens and adolescents for HPV vaccine
could draw fire. J Natl Cancer Inst. 2005; 97: 1030–1031.
22. Coker AL, Bond S, Madeleine MM, Luchok K, Pirisi L.
Psychosocial stress and cervical neoplasia risk. Psychosom Med.
2003; 65: 644–651.
23. Pereira DB, Antoni MH, Danielson A, et al. Life stress and
cervical squamous intraepithelial lesions in women with human
papillomavirus and human immunodeficiency virus. Psychosom
Med. 2003; 65: 427–434.
24. Glaser R, Kiecolt-Glaser JK. Chronic stress modulates the virus-
specific immune response to latent herpes simplex virus type 1.
Annals Behav Med. 1997; 19: 78–82.
25. Kang DH, Fox C. Neuroendocrine and leukocyte responses and
pulmonary function to acute stressors. Annals of Behav Med.
2000; 22: 276–285.
26. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Psychoneu-
roimmunology: Psychological influences on immune function and
health. J Consult Clin Psychol. 2002; 70: 537–547.
27. Kiecolt-Glaser JK, Robles TF, Heffner KL, Loving TJ, Glaser R.
Psycho-oncology and cancer: psychoneuroimmunology and can-
cer. Ann Oncol. 2002; 13(Suppl 4): 165–169.
28. DeLongis A, Coyne J, Dakof G, Folkman S, Lazarus RS.
Relationship of daily hassles, uplifts, and major life events to
health status. Health Psychol. 1982; 1: 119–136.
29. Holmes TH, Rahe RH. The social readjustment rating scale. J
Psychosom Res. 1967; 11: 213–218.
30. Cohen S, Kamarck TW, Mermelstein R. A global measure of
perceived stress. J Health Soc Behav. 1983; 24: 385–396.
31. Cohen S, Doyle WJ, Skoner DP. Psychological stress, cytokine
production, and severity of upper respiratory illness. Psychosom
Med. 1999; 61: 175–180.
32. Cohen S, Hamrick N, Rodriguez MS, et al. Reactivity and
vulnerability to stress-associated risk for upper respiratory illness.
Psychosom Med. 2002; 64: 302–310.
33. Cohen S, Miller G, Rabin B. Psychological stress and antibody
response to immunization: A critical review of the human
literature. Psychosom Med. 2001; 63: 7–18.
34. Cohen S, Rabin BS. Psychologic stress, immunity, and cancer. J
Natl Cancer Inst. 1998; 90: 3–4.
35. Cohen S, Tyrrell DA, Smith AP. Psychological stress and suscepti-
bility to the common cold. N Engl J Med. 1991; 325: 606–612.
36. Luxton JC, Rowe AJ, Cridland JC, et al. Proliferative T cell
responses to the human papillomavirus type 16 E7 protein in
women with cervical dysplasia and cervical carcinoma and in
healthy individuals. J Gen Virol. 1996; 77: 1585–1593.
37. Nakagawa M, Stites DP, Farhat S, et al. T-cell proliferative
response to human papillomavirus type 16 peptides: Relationship
to cervical intraepithelial neoplasia. Clin Diagn Lab Immunol.
1996; 3: 205–210.
38. Douglas SD, Hoffman PF, Borjeson J, Chessin LN. Studies on
human peripheral blood lymphocytes in vitro. 3. Fine structural
features of lymphocyte transformation by pokeweed mitogen. J
Immunol. 1967; 98: 17–30.
39. Douglas SD, Kamin RM, Fudenberg HH. Human lymphocyte
response to phytomitogens in vitro: normal, agammaglobulinemic
and paraproteinemic individuals. J Immunol. 1969; 103: 1185–1195.
40. Borkowsky W, Stanley K, Douglas SD, et al. Immunologic response
to combination nucleoside analogue plus protease inhibitor therapy in
stable antiretroviral therapy-experienced human immunodeficiency
virus-infected children. J Infect Dis. 2000; 182: 96–103.
41. Sarkar AK, Tortolero-Luna G, Follen M, Sastry KJ. Inverse
correlation of cellular immune responses specific to synthetic
peptides from the E6 and E7 oncoproteins of HPV-16 with
recurrence of cervical intraepithelial neoplasia in a cross-sectional
study. Gynecol Oncol. 2005; 99: S251–S261.
42. Fang CY, Miller SM, Mills M, et al. The effects of avoidance on
cytotoxic/suppressor T cells in women with cervical lesions.
Psychooncology. 2003; 12: 590–598.
43. Gill D, Bible J, Biswas C, et al. Proliferative T-cell responses to
human papillomavirus type 16 E5 are decreased amongst women
with high-grade neoplasia. J Gen Virol. 1998; 79: 1971–1976.
44. Steele JC, Mann CH, Rookes S, et al. T-cell responses to human
papillomavirus type 16 among women with different grades of
cervical neoplasia. Br J Cancer. 2005; 93: 248–259.
45. Brummer O, Hollwitz B, Bohmer G, Kuhnle H, Petry KU. Human
papillomavirus-type persistence patterns predict the clinical out-
come of cervical intraepithelial neoplasia. Gynecol Oncol. 2006;
102: 517–522.
46. Goodkin K, Antoni MH, Blaney PH. Stress and hopelessness in the
promotion of cervical intraepithelial neoplasia to invasive squamous
cell carcinoma of the cervix. J Psychosom Res. 1986; 30: 67–76.
47. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Psychoneu-
roimmunology and psychosomatic medicine: Back to the future.
Psychosom Med. 2002; 64: 15–28.
48. Paik IH, Toh KY, Lee C, Kim JJ, Lee SJ. Psychological stress may
induce increased humoral and decreased cellular immunity. Behav
Med. 2000; 26: 139–141.
ann. behav. med. (2008) 35:87–96 95
49. Clerici M,Merola M, Ferrario E, et al. Cytokine production patterns
in cervical intraepithelial neoplasia: association with human
papillomavirus infection. J Natl Cancer Inst. 1997; 89: 245–250.
50. Peralta-Ramirez MI, Jimenez-Alonso J, Godoy-Garcia JF, Perez-
Garcia M. The effects of daily stress and stressful life events on
the clinical symptomatology of patients with lupus erythematosus.
Psychosom Med. 2004; 66: 788–794.
51. Hamrick N, Cohen S, Rodriguez MS. Being popular can be
healthy or unhealthy: stress, social network diversity, and
incidence of upper respiratory infection. Health Psychol. 2002;
21: 294–298.
52. Folkman S. Personal control and stress and coping processes: A
theoretical analysis. J Pers Soc Psychol. 1984; 46: 839–852.
53. Folkman S, Lazarus RS, Dunkel-Schetter C, De Longis A, Gruen RJ.
Dynamics of a stressful encounter: Cognitive appraisal, coping,
and encounter outcomes. J Pers Soc Psychol. 1986; 50: 992–
1003.
54. Maier KJ, Waldstein SR, Synowski SJ. Relation of cognitive
appraisal to cardiovascular reactivity, affect, and task engagement.
Annals Behav Med. 2003; 26: 32–41.
55. Bontkes HJ, de Gruijl TD, Walboomers JM, et al. Immune
responses against human papillomavirus (HPV) type 16 virus-like
particles in a cohort study of women with cervical intraepithelial
neoplasia. II. Systemic but not local IgA responses correlate
with clearance of HPV-16. J Gen Virol. 1999; 80(Pt 2): 409–
417.
96 ann. behav. med. (2008) 35:87–96
